Jeffrey Statland, MD
Neuromuscular Medicine · Kansas City, KSNPI 1578781209
Payments from drug & device makers
Across 435 payments — averaging $6579.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$621K
- Genentech, Inc.$497K
- PTC Therapeutics, Inc.$403K
- Novartis$359K
- Vertex$226K
- Roche Products Limited$176K
- plus $581K from 21 others
Across 5 payments — averaging $672.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1K
- F. Hoffmann-la Roche AG$1K
- NS Pharma, Inc.$721
What the payments were for
- Consulting fees$40,02682%
- Speaking & faculty fees$4,79010%
- Travel & lodging$3,2097%
- Food & beverage$6561%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 146 | $621,269 |
| Genentech, Inc. | 31 | $496,788 |
| PTC Therapeutics, Inc. | 111 | $402,686 |
| Novartis | 6 | $359,234 |
| Vertex | 5 | $225,592 |
| Roche Products Limited | 24 | $175,967 |
| Pfizer | 24 | $116,410 |
| F. Hoffmann-la Roche AG | 3 | $105,023 |
| NS Pharma, Inc. | 22 | $85,416 |
| Hoffmann-la Roche Limited | 11 | $81,732 |
| Astellas Pharma Inc | 10 | $59,869 |
| Harmony Biosciences LLC | 7 | $45,115 |
| Amylyx Pharmaceuticals, Inc. | 2 | $27,601 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 12 | $21,020 |
| Catalyst Pharmaceuticals, Inc. | 1 | $19,688 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 4 | $3,400 |
| Merck | 2 | $3,090 |
| Sanofi | 1 | $3,006 |
| Sanofi-aventis U.S. LLC | 1 | $2,572 |
| Lupin Inc. | 1 | $2,438 |
| Siemens Medical Solutions USA, Inc. | 3 | $1,819 |
| ITF Therapeutics LLC | 1 | $1,590 |
| Ionis Pharmaceuticals, Inc. | 2 | $650 |
| EDW Pharma, Inc. | 1 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $103 |
| Tanabe Pharma America, Inc. | 1 | $28 |
| Biogen | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Exondys 51$9,938
- LUMIZYME$3,006
- Tiglutik$132
How this compares
Too few neuromuscular medicine providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 178 | $2,468,658 |
| TeglutikRiluzole | 18 | $69,118 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $41,746 |
| Riluzole | 101 | $12,584 |
| Tizanidine Hcl | 52 | $2,190 |
| Baclofen | 46 | $2,075 |
| Mexiletine Hcl | 23 | $2,020 |
| Atropine Sulfate | 16 | $1,062 |
| Glycopyrrolate | 28 | $1,035 |
| Gabapentin | 42 | $652 |
| Pregabalin | 18 | $252 |
| Escitalopram Oxalate | 12 | $200 |
| Diazepam | 28 | $123 |
| Nortriptyline Hcl | 12 | $117 |
| Duloxetine Hcl | 11 | $112 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Kansas City
- Long DavalosKansas City$554
- Mustafa Al-KharsanKansas City$180
- Matthew VaronKansas City$129
- Ahmad AbuzinadahKansas City$19
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.